胰腺癌患者血循环miR-429的表达及其临床意义
|
摘要
目的:检测胰腺癌患者血浆miR-429表达水平,分析其表达与胰腺癌临床病理学特征的关系。方法:定量PCR检测BXPC-3、PANC-1细胞株以及3例胰腺癌组织中miR-429的表达水平。收集未经治疗的37例胰腺癌患者的血浆标本,采用实时定量PCR法检测miR-429表达水平,收集胰腺癌患者的临床病理学参数(年龄、临床分期、分化程度、组织类型及淋巴结转移情况),比较不同miR-429水平的临床病理参数分布差异。结果:相较于正常胰腺细胞、胰腺组织,miR-429在胰腺癌细胞株和癌组织中均处于低表达水平(P<0.05)。miR-429表达与肿瘤大小、TNM临床分期、神经浸润以及生存期密切相关,均有统计学差异(P<0.05)。结论:循环血miR-429的表达可能成为胰腺癌早期诊断、预后判断的指标。
Objective: To investigate the expression of miR-429 in pancreatic cancer and explore the relationship between the expression of miR-429 and its clinical pathology features. Methods: The expression of miR-429 in BXPC-3,PANC-1 cells and pancreatic cancer tissues were inspected by Real-time PCR. Collect serum from 37 patients with pancreatic cancer. Real-time PCR was conducted to measure miR-429 expression in the serum of pancreatic cancer patients. The relationship between miR-429 expression and pathological features were analyzed. Results: miR-429 was observed down-regulated in pancreatic cancer cell lines,tissue and in patient 's serum( P <0. 05). The statistical analysis suggested that miR-429 was associated with tumor size,TNM stage,nerves infiltration and survival( P < 0. 05). Conclusion: The expression of miR-429 in serum could be a new biomarker for pancreatic cancer early diagnosis and predictor of prognosis.
Objective: To investigate the expression of miR-429 in pancreatic cancer and explore the relationship between the expression of miR-429 and its clinical pathology features. Methods: The expression of miR-429 in BXPC-3,PANC-1 cells and pancreatic cancer tissues were inspected by Real-time PCR. Collect serum from 37 patients with pancreatic cancer. Real-time PCR was conducted to measure miR-429 expression in the serum of pancreatic cancer patients. The relationship between miR-429 expression and pathological features were analyzed. Results: miR-429 was observed down-regulated in pancreatic cancer cell lines,tissue and in patient 's serum( P <0. 05). The statistical analysis suggested that miR-429 was associated with tumor size,TNM stage,nerves infiltration and survival( P < 0. 05). Conclusion: The expression of miR-429 in serum could be a new biomarker for pancreatic cancer early diagnosis and predictor of prognosis.
引文
[1]Amponsah PS,Fan P,Bauer N,et al.microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer[J].Cancer Lett,2017,388:107-117.
[2]Alemar B,Izetti P,Gregorio C,et al.miRNA-21 and miRNA-34a are potential minimally invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma[J].Pancreas,2016,45:84-92.
[3]Fest J,Ruiter R,van Rooij FJ,et al.Underestimation of pancreatic cancer in the national cancer registry-reconsidering the incidence and survival rates[J].Eur J Cancer,2017,72:186-191.
[4]Zhang R,Hardin H,Chen J,et al.Non-coding RNAs in thyroid cancer[J].Endocr Pathol,2016,27:12-20.
[5]Kuninty PR,Schnittert J,Storm G,et al.MicroRNA targeting to modulate tumor microenvironment[J].Front Oncol,2016,6:3.
[6]Bhattacharyya M,Nath J,Bandyopadhyay S.Identifying significant microRNA-mRNA pairs associated with breast cancer subtypes[J].Mol Biol Rep,2016,43:591-599.
[7]Bhattacharyya NP,Das E,Bucha S,et al.Regulation of cell cycle associated genes by microRNA and transcription factor[J].Microrna,2016,5:180-200.
[8]Li J,Wu H,Li W,et al.Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-kappa B signaling[J].Oncogene,2016,35:5501-5514.
[9]Zampetaki A,Willeit P,Drozdov I,et al.Profiling of circulating microRNAs:from single biomarkers to re-wired networks[J].Cardiovasc Res,2012,93:555-562.
[10]Tavallaie R,De Almeida SR,Gooding JJ.Toward biosensors for the detection of circulating microRNA as a cancer biomarker:an overview of the challenges and successes[J].Wiley Interdiscip Rev Nanomed Nanobiotechnol,2015,7:580-592.
[11]Elghoroury EA,El Dine HG,Kamel SA,et al.Evaluation of miRNA-21 and miRNA Let-7 as prognostic markers in patients with breast cancer[J].Clin Breast Cancer,2017.doi:10.1016/j.clbc.2017.11.022.
[12]Moridikia A,Mirzaei H,Sahebkar A,et al MicroRNAs:Potential candidates for diagnosis and treatment of colorectal cancer[J].J Cell Physiol,2018,233(2):901-913.
[13]Chen X,Hu Z,Wang W,et al.Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis[J].Int J Cancer,2012,130:1620-1628.
[14]Xiong DD,Lv J,Wei KL,et al.A nine-miRNA signature as a potential diagnostic marker for breast carcinoma:An integrated study of 1 110 cases[J].Oncol Rep,2017,37:3297-3304.
[15]Ya G,Wang H,Ma Y,et al.Serum miR-129 functions as a biomarker for colorectal cancer by targeting estrogen receptor(ER)beta[J].Pharmazie,2017,72:107-112.
[16]Abue M,Yokoyama M,Shibuya R,et al.Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer[J].Int J Oncol,2015,46:539-547.
[17]Xiong J,Wang D,Wei A,et al.Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN[J].Exp Cell Res,2017,361:316-323.
[18]Pizzamiglio S,Zanutto S,Ciniselli CM,et al.A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs[J].Oncol Lett,2017,13:315-320.
[2]Alemar B,Izetti P,Gregorio C,et al.miRNA-21 and miRNA-34a are potential minimally invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma[J].Pancreas,2016,45:84-92.
[3]Fest J,Ruiter R,van Rooij FJ,et al.Underestimation of pancreatic cancer in the national cancer registry-reconsidering the incidence and survival rates[J].Eur J Cancer,2017,72:186-191.
[4]Zhang R,Hardin H,Chen J,et al.Non-coding RNAs in thyroid cancer[J].Endocr Pathol,2016,27:12-20.
[5]Kuninty PR,Schnittert J,Storm G,et al.MicroRNA targeting to modulate tumor microenvironment[J].Front Oncol,2016,6:3.
[6]Bhattacharyya M,Nath J,Bandyopadhyay S.Identifying significant microRNA-mRNA pairs associated with breast cancer subtypes[J].Mol Biol Rep,2016,43:591-599.
[7]Bhattacharyya NP,Das E,Bucha S,et al.Regulation of cell cycle associated genes by microRNA and transcription factor[J].Microrna,2016,5:180-200.
[8]Li J,Wu H,Li W,et al.Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-kappa B signaling[J].Oncogene,2016,35:5501-5514.
[9]Zampetaki A,Willeit P,Drozdov I,et al.Profiling of circulating microRNAs:from single biomarkers to re-wired networks[J].Cardiovasc Res,2012,93:555-562.
[10]Tavallaie R,De Almeida SR,Gooding JJ.Toward biosensors for the detection of circulating microRNA as a cancer biomarker:an overview of the challenges and successes[J].Wiley Interdiscip Rev Nanomed Nanobiotechnol,2015,7:580-592.
[11]Elghoroury EA,El Dine HG,Kamel SA,et al.Evaluation of miRNA-21 and miRNA Let-7 as prognostic markers in patients with breast cancer[J].Clin Breast Cancer,2017.doi:10.1016/j.clbc.2017.11.022.
[12]Moridikia A,Mirzaei H,Sahebkar A,et al MicroRNAs:Potential candidates for diagnosis and treatment of colorectal cancer[J].J Cell Physiol,2018,233(2):901-913.
[13]Chen X,Hu Z,Wang W,et al.Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis[J].Int J Cancer,2012,130:1620-1628.
[14]Xiong DD,Lv J,Wei KL,et al.A nine-miRNA signature as a potential diagnostic marker for breast carcinoma:An integrated study of 1 110 cases[J].Oncol Rep,2017,37:3297-3304.
[15]Ya G,Wang H,Ma Y,et al.Serum miR-129 functions as a biomarker for colorectal cancer by targeting estrogen receptor(ER)beta[J].Pharmazie,2017,72:107-112.
[16]Abue M,Yokoyama M,Shibuya R,et al.Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer[J].Int J Oncol,2015,46:539-547.
[17]Xiong J,Wang D,Wei A,et al.Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN[J].Exp Cell Res,2017,361:316-323.
[18]Pizzamiglio S,Zanutto S,Ciniselli CM,et al.A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs[J].Oncol Lett,2017,13:315-320.